| Langerhans cell histiocytosis in neonates. | |
| | |
MedLine Citation:
|
PMID: 15770639 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: To study the incidence, clinical patterns, course, and outcome of neonatal Langerhans cell histiocytosis (LCH). PROCEDURE: Retrospective analysis of the data of the Austrian/German/Swiss/Netherlands LCH Study Group. The incidence of neonatal LCH was estimated with the data from the population-based German Childhood Cancer Registry. RESULTS: The estimated incidence of neonatal LCH (LCH diagnosed within 28 days after birth) in the population-based registry was 1-2/1,000,000. In 61/1,069 trial patients (6%), the first disease manifestations were observed in the neonatal period. However, in only 20 of them, the diagnosis was established within this period. There was a preponderance of multisystem (MS)-LCH 36/61 (59%). Cutaneous changes were the most common initial manifestation in both, single-system (SS)-LCH (92%), and MS-LCH (86%). In 72% of the MS-LCH patients, risk organs (ROs) were involved at diagnosis as well. The probability of survival at 5 years was 94% in SS-LCH and 57% in MS-LCH, which is significantly lower than in older age groups. CONCLUSIONS: In contrast to the available literature, neonatal LCH is characterized by a clear predominance of MS-LCH. Cutaneous changes are the most common initial manifestation in neonates with both SS-LCH and MS-LCH. Prompt evaluation of disease extent upon diagnosis is mandatory for risk-adapted treatment. The disease course is unpredictable upon diagnosis. Close monitoring for disease progression is mandatory if isolated cutaneous LCH is managed by the "wait and see" approach. Neonates with MS-LCH, especially those with RO involvement at diagnosis, have less favorable prognosis compared to infants and older children, and need systemic therapy. |
| | |
Authors:
|
M Minkov; H Prosch; M Steiner; N Grois; U Pötschger; P Kaatsch; G Janka-Schaub; H Gadner |
Related Documents
:
|
20645239 - The apparently stillborn infant: risk factors, incidence, and neonatal outcome. 9990199 - The femoral sulcus angle in neonatal cadavers: a macroscopical and ultrasonographical s... 18810399 - Clinical pharmacokinetics of penicillins in the neonate: a review of the literature. 3342599 - Persistent neonatal hyperinsulinism. 6848309 - Potentiation of magnesium-induced neuromuscular weakness by gentamicin. 7993799 - A case of severe neonatal thrombocytopenia with schizencephaly associated with anti-hpa... 856869 - Quantitative determination of antibody to capsular polysaccharide in infection with typ... 8039989 - Fentanyl-induced chest wall rigidity in a neonate: a case report. 21311509 - Longitudinal body composition data in exclusively breast-fed infants: a multicenter study. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pediatric blood & cancer Volume: 45 ISSN: 1545-5009 ISO Abbreviation: Pediatr Blood Cancer Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-09-19 Completed Date: 2005-12-28 Revised Date: 2009-01-12 |
Medline Journal Info:
|
Nlm Unique ID: 101186624 Medline TA: Pediatr Blood Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 802-7 Citation Subset: IM |
Copyright Information:
|
(c) 2005 Wiley-Liss, Inc. |
Affiliation:
|
St. Anna Children's Hospital, Vienna, Austria. milen.minkov@Stanna.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Disease Progression Female Histiocytosis, Langerhans-Cell / diagnosis, epidemiology*, mortality, therapy Humans Incidence Infant, Newborn Male Prognosis Registries Retrospective Studies Risk Assessment Skin Diseases Survival Analysis |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia tr...
Next Document: Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-...